PMC:7228307 / 37860-38257 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"639","span":{"begin":23,"end":27},"obj":"Gene"},{"id":"640","span":{"begin":392,"end":396},"obj":"Gene"},{"id":"641","span":{"begin":222,"end":226},"obj":"Gene"}],"attributes":[{"id":"A639","pred":"tao:has_database_id","subj":"639","obj":"Gene:2213"},{"id":"A640","pred":"tao:has_database_id","subj":"640","obj":"Gene:2213"},{"id":"A641","pred":"tao:has_database_id","subj":"641","obj":"Gene:2213"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Many factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T341","span":{"begin":214,"end":217},"obj":"Body_part"},{"id":"T342","span":{"begin":270,"end":275},"obj":"Body_part"}],"attributes":[{"id":"A341","pred":"fma_id","subj":"T341","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A342","pred":"fma_id","subj":"T342","obj":"http://purl.org/sig/ont/fma/fma9576"}],"text":"Many factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T21","span":{"begin":270,"end":275},"obj":"Body_part"}],"attributes":[{"id":"A21","pred":"uberon_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"}],"text":"Many factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T691","span":{"begin":23,"end":25},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T692","span":{"begin":222,"end":224},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T693","span":{"begin":264,"end":265},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T694","span":{"begin":270,"end":275},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"},{"id":"T695","span":{"begin":392,"end":394},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"Many factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"639","span":{"begin":23,"end":27},"obj":"Gene"},{"id":"641","span":{"begin":222,"end":226},"obj":"Gene"}],"attributes":[{"id":"A641","pred":"pubann:denotes","subj":"641","obj":"Gene:2213"},{"id":"A639","pred":"pubann:denotes","subj":"639","obj":"Gene:2213"}],"text":"Many factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T215","span":{"begin":0,"end":90},"obj":"Sentence"},{"id":"T216","span":{"begin":91,"end":397},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Many factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR."}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T21","span":{"begin":270,"end":275},"obj":"Body_part"}],"attributes":[{"id":"A21","pred":"uberon_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"}],"text":"Many factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T340","span":{"begin":214,"end":217},"obj":"Body_part"},{"id":"T341","span":{"begin":270,"end":275},"obj":"Body_part"}],"attributes":[{"id":"A341","pred":"fma_id","subj":"T341","obj":"http://purl.org/sig/ont/fma/fma9576"},{"id":"A340","pred":"fma_id","subj":"T340","obj":"http://purl.org/sig/ont/fma/fma62872"}],"text":"Many factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR."}

{"project":"LitCovid-sentences","denotations":[{"id":"T215","span":{"begin":0,"end":90},"obj":"Sentence"},{"id":"T216","span":{"begin":91,"end":397},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Many factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR."}